HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
SGEN [NASD]
Seagen Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-3.77 Insider Own0.60% Shs Outstand183.65M Perf Week31.00%
Market Cap24.59B Forward P/E- EPS next Y-1.22 Insider Trans-35.69% Shs Float182.57M Perf Month-4.80%
Income-689.50M PEG- EPS next Q-0.86 Inst Own90.60% Short Float1.60% Perf Quarter14.48%
Sales1.67B P/S14.73 EPS this Y-210.10% Inst Trans-1.76% Short Ratio2.75 Perf Half Y-20.37%
Book/sh16.33 P/B8.73 EPS next Y75.60% ROA-18.10% Target Price159.88 Perf Year-3.68%
Cash/sh11.31 P/C12.60 EPS next 5Y39.20% ROE-21.90% 52W Range105.43 - 192.79 Perf YTD-7.80%
Dividend- P/FCF- EPS past 5Y-30.10% ROI-22.20% 52W High-26.06% Beta0.84
Dividend %- Quick Ratio4.70 Sales past 5Y30.40% Gross Margin79.90% 52W Low35.20% ATR7.74
Employees2675 Current Ratio5.20 Sales Q/Q28.50% Oper. Margin-41.50% RSI (14)57.99 Volatility7.45% 5.17%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.90% Profit Margin-41.30% Rel Volume1.91 Prev Close135.63
ShortableYes LT Debt/Eq0.00 EarningsApr 28 AMC Payout- Avg Volume1.06M Price142.54
Recom2.10 SMA208.31% SMA502.97% SMA200-5.76% Volume2,010,624 Change5.09%
Feb-10-22Reiterated Wolfe Research Peer Perform $195 → $146
Feb-10-22Reiterated SVB Leerink Outperform $179 → $155
Feb-10-22Reiterated RBC Capital Mkts Sector Perform $154 → $132
Feb-10-22Reiterated Piper Sandler Neutral $165 → $150
Feb-10-22Reiterated Needham Buy $200 → $180
Feb-10-22Reiterated Morgan Stanley Overweight $175 → $170
Feb-10-22Reiterated H.C. Wainwright Buy $200 → $170
Feb-10-22Reiterated BofA Securities Buy $210 → $170
Jan-31-22Upgrade Morgan Stanley Equal-Weight → Overweight $178 → $175
Nov-09-21Initiated Wolfe Research Peer Perform $195
Oct-15-21Resumed BTIG Research Neutral
May-17-21Initiated Evercore ISI In-line
Mar-31-21Initiated Credit Suisse Neutral $145
Feb-01-21Downgrade RBC Capital Mkts Outperform → Sector Perform $188 → $186
Jan-15-21Upgrade BofA Securities Neutral → Buy $215
Sep-22-20Reiterated Stifel Hold $145 → $165
Aug-24-20Resumed Berenberg Buy $187
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-16-22 02:02PM  
Seagen CEO steps down after domestic violence arrest
American City Business Journals +5.09%
06:00AM  
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
Business Wire
May-12-22 10:57AM  
Recent 10.0% pullback isn't enough to hurt long-term Seagen (NASDAQ:SGEN) shareholders, they're still up 90% over 5 years
Simply Wall St. +6.40%
May-09-22 04:33PM  
Seagen CEO goes on leave amid domestic violence allegations
American City Business Journals -11.85%
04:08PM  
Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim
Investor's Business Daily
06:00AM  
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
Business Wire
Apr-28-22 05:45PM  
Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates
Zacks
04:02PM  
Seagen Reports First Quarter 2022 Financial Results
Business Wire
08:00AM  
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire
Apr-22-22 12:14AM  
Construction underway on Seagen biomanufacturing facility in Everett
American City Business Journals
Apr-21-22 03:01PM  
Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for
Zacks
Apr-20-22 09:00AM  
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
Business Wire
Apr-13-22 11:45AM  
European Commission Approves PADCEV (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
PR Newswire
11:45AM  
European Commission Approves PADCEV (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
Business Wire
Apr-08-22 03:23PM  
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
Business Wire
01:19PM  
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
Business Wire
Apr-07-22 08:00AM  
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
Business Wire
Mar-16-22 06:30AM  
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
Business Wire
Mar-11-22 11:30AM  
Why Is Seattle Genetics (SGEN) Up 12.7% Since Last Earnings Report?
Zacks
Mar-01-22 08:00AM  
Seagen to Present at the Cowen 42nd Annual Health Care Conference
Business Wire
Feb-28-22 08:00AM  
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
PR Newswire
08:00AM  
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
Business Wire
Feb-24-22 10:00AM  
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Business Wire +5.57%
10:00AM  
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Business Wire
Feb-16-22 05:20AM  
Downgrade: Here's How Analysts See Seagen Inc. (NASDAQ:SGEN) Performing In The Near Term
Simply Wall St.
Feb-14-22 05:00PM  
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
Business Wire
05:00PM  
Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
PR Newswire
Feb-09-22 05:15PM  
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
Zacks
04:02PM  
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
Business Wire
Feb-08-22 09:38AM  
Sivik Global Healthcare LLC Buys SPDR Biotech ETF, Anthem Inc, Universal Health Services Inc, ...
GuruFocus.com
08:00AM  
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Business Wire
Feb-07-22 09:38PM  
North Star Asset Management Inc Buys Navient Corp, Intuitive Surgical Inc, Catalent Inc, Sells ...
GuruFocus.com
Feb-04-22 03:59PM  
Did Hedge Funds Get Seagen Inc. (SGEN) Right?
Insider Monkey
Feb-03-22 08:00AM  
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
Business Wire
Feb-02-22 03:01PM  
Earnings Preview: Seattle Genetics (SGEN) Q4 Earnings Expected to Decline
Zacks
01:38PM  
Integral Health Asset Management, LLC Buys McKesson Corp, Centene Corp, Abbott Laboratories, ...
GuruFocus.com
Feb-01-22 08:00AM  
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
Business Wire
Jan-24-22 01:38PM  
EFG Asset Management (Americas) Corp. Buys Tesla Inc, Microsoft Corp, Dick's Sporting Goods ...
GuruFocus.com
Jan-18-22 05:00PM  
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
Business Wire
08:00AM  
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
Business Wire
Jan-17-22 10:53AM  
Seagen (NASDAQ:SGEN) Is In A Strong Position To Grow Its Business
Simply Wall St.
Dec-24-21 12:38AM  
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...
GuruFocus.com
Dec-23-21 08:38AM  
MainStay VP Wellington U.S. Equity Portfolio Buys VF Corp, Seagen Inc, Sells Under Armour Inc, ...
GuruFocus.com
Dec-21-21 06:38PM  
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
GuruFocus.com
Dec-20-21 08:00AM  
Seagen to Present at the J.P. Morgan Healthcare Conference
Business Wire
Dec-19-21 06:38AM  
Voya VARIABLE PRODUCTS TRUST Buys Avalara Inc, Bio-Techne Corp, Roku Inc, Sells Spotify ...
GuruFocus.com
Dec-18-21 12:38AM  
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...
GuruFocus.com
Dec-17-21 06:40AM  
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
PR Newswire
Dec-15-21 12:38AM  
Tributary Growth Opportunities Fund Buys GXO Logistics Inc, Tandem Diabetes Care Inc, Paychex ...
GuruFocus.com
Dec-13-21 04:38PM  
Invesco V.I. Main Street Fund Buys Salesforce. ...
GuruFocus.com
Dec-12-21 06:00PM  
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
Business Wire
Dec-09-21 10:15PM  
Seagen Inc (SGEN) President & CEO Clay B Siegall Sold $6.8 million of Shares
GuruFocus.com
05:38PM  
Azzad Funds Buys Heico Corp, CoStar Group Inc, Zimmer Biomet Holdings Inc, Sells Zendesk Inc, ...
GuruFocus.com
06:38AM  
Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients
Benzinga
Dec-08-21 10:05PM  
Hedge Funds Are Piling Into Seagen Inc. (SGEN)
Insider Monkey
06:00PM  
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
Business Wire
Nov-19-21 09:33AM  
Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Business Wire
Nov-15-21 10:44AM  
Notable Seagen Insider Trades $1.2M In Company Stock
Benzinga
Nov-09-21 08:54AM  
Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
Business Wire
Nov-04-21 09:31AM  
Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
Business Wire
Oct-29-21 07:01AM  
Seattle Genetics (SGEN) Q3 2021 Earnings Call Transcript
Motley Fool
Oct-28-21 05:45PM  
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:02PM  
Seagen Reports Third Quarter 2021 Financial Results
Business Wire
Oct-21-21 03:03PM  
Earnings Preview: Seattle Genetics (SGEN) Q3 Earnings Expected to Decline
Zacks
Oct-19-21 01:09PM  
Is Seagen Inc.'s(NASDAQ:SGEN) Recent Stock Performance Tethered To Its Strong Fundamentals?
Simply Wall St.
Oct-12-21 09:35AM  
Is Seagen Inc. (SGEN) A Good Stock To Buy?
Insider Monkey
08:00AM  
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Business Wire
08:00AM  
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
PR Newswire
Oct-07-21 08:00AM  
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
Business Wire
Sep-28-21 08:00AM  
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
Business Wire
Sep-27-21 03:00AM  
Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
PR Newswire
03:00AM  
Japans MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
Business Wire
Sep-20-21 05:05PM  
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK (tisotumab vedotin-tftv) Approval
Business Wire
05:03PM  
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Business Wire
05:00PM  
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Business Wire
Sep-19-21 11:30AM  
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Business Wire
Sep-13-21 11:18AM  
Chief Technical Officer Of Seagen Trades $1.06 Million In Company Stock
Benzinga
Sep-09-21 08:00AM  
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Business Wire
Sep-08-21 08:00AM  
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
Business Wire
Aug-17-21 01:15PM  
Investing in Seagen (NASDAQ:SGEN) five years ago would have delivered you a 231% gain
Simply Wall St.
Aug-09-21 06:00AM  
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
Business Wire
Jul-30-21 10:03AM  
Seattle Genetics (SGEN) Q2 2021 Earnings Call Transcript
Motley Fool
Jul-29-21 05:25PM  
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
Zacks
04:02PM  
Seagen Reports Second Quarter 2021 Financial Results
Business Wire
Jul-22-21 03:03PM  
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks
Jul-09-21 02:10PM  
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
PR Newswire
02:10PM  
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Business Wire
Jul-08-21 08:00AM  
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021
Business Wire
Jun-28-21 09:43AM  
Hedge Funds Have Never Been This Bullish On Seagen Inc. (SGEN)
Insider Monkey
Jun-16-21 06:38AM  
Seagen Inc. (NASDAQ:SGEN) Shares Could Be 38% Below Their Intrinsic Value Estimate
Simply Wall St.
Jun-03-21 06:00AM  
Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting
Business Wire
Jun-02-21 08:00AM  
Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Business Wire
May-25-21 01:12PM  
Top Healthcare Stocks for June 2021
Investopedia
May-19-21 05:00PM  
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
Business Wire
05:00PM  
Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
PR Newswire
Apr-30-21 03:01AM  
Seattle Genetics (SGEN) Q1 2021 Earnings Call Transcript
Motley Fool
Apr-29-21 05:25PM  
Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
Zacks
04:02PM  
Seagen Reports First Quarter 2021 Financial Results
Business Wire
02:30PM  
Seagen Inc. to Host Earnings Call
ACCESSWIRE
08:00AM  
Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
Business Wire
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident & CEOMay 12Option Exercise26.1017,043444,822676,653May 13 07:13 PM
SIEGALL CLAY BPresident & CEOMay 12Sale125.6917,0432,142,117666,060May 13 07:13 PM
DANSEY ROGER DChief Medical OfficerApr 21Sale144.1565293,98676,975Apr 22 08:27 PM
SIEGALL CLAY BPresident & CEOApr 20Sale144.321,885272,041666,060Apr 22 08:34 PM
SIMPSON TODD EChief Financial OfficerApr 20Sale144.3256781,829127,891Apr 22 08:32 PM
LIU JEAN IChief Legal OfficerApr 20Sale144.3240157,87275,946Apr 22 08:31 PM
ROMP CHARLES REVP, CommercialApr 20Sale144.3231946,03849,816Apr 22 08:30 PM
HIMES VAUGHN BChief Technical OfficerApr 20Sale144.3257482,83959,064Apr 22 08:29 PM
DANSEY ROGER DChief Medical OfficerApr 20Sale144.32787113,57977,627Apr 22 08:27 PM
GRYSKA DAVID WDirectorApr 19Option Exercise20.064,00080,24048,044Apr 21 06:37 PM
GRYSKA DAVID WDirectorApr 19Sale143.954,000575,78346,250Apr 21 06:37 PM
SIEGALL CLAY BPresident and CEOApr 07Option Exercise26.1017,043444,822672,637Apr 08 09:41 PM
SIEGALL CLAY BPresident and CEOApr 07Sale154.2317,0432,628,610667,945Apr 08 09:41 PM
BAKER BROS. ADVISORS LPDirectorMar 08Option Exercise20.0635,000702,10042,965,004Mar 10 04:39 PM
SIEGALL CLAY BPresident & CEOMar 07Option Exercise26.1017,043444,822674,588Mar 09 07:42 PM
SIEGALL CLAY BPresident & CEOMar 07Sale134.3517,0432,289,655667,945Mar 09 07:42 PM
HIMES VAUGHN BChief Technical OfficerMar 03Option Exercise26.1012,000313,20070,343Mar 04 07:24 PM
HIMES VAUGHN BChief Technical OfficerMar 03Sale127.0512,0001,524,55859,500Mar 04 07:24 PM
Simonian Nancy ADirectorMar 02Option Exercise20.0425,000501,00052,500Mar 04 05:09 PM
GRYSKA DAVID WDirectorFeb 07Option Exercise20.064,50090,27048,621Feb 09 06:58 PM
SIEGALL CLAY BPresident & CEOFeb 07Option Exercise26.1017,043444,822676,930Feb 09 07:02 PM
GRYSKA DAVID WDirectorFeb 07Sale138.764,500624,44146,250Feb 09 06:58 PM
SIEGALL CLAY BPresident & CEOFeb 07Sale139.9717,0432,385,566667,945Feb 09 07:02 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale136.1470395,70678,244Feb 04 05:54 PM
DANSEY ROGER DChief Medical OfficerFeb 02Sale137.58739101,67278,947Feb 04 05:54 PM
GRYSKA DAVID WDirectorJan 28Option Exercise20.064,50090,27048,803Feb 01 06:42 PM
GRYSKA DAVID WDirectorJan 28Sale122.564,500551,53946,250Feb 01 06:42 PM
GRYSKA DAVID WDirectorJan 14Option Exercise20.064,50090,27050,750Jan 19 06:26 PM
GRYSKA DAVID WDirectorJan 14Sale135.244,500608,58146,250Jan 19 06:26 PM
SIEGALL CLAY BPresident & CEOJan 07Option Exercise26.1017,044444,848676,108Jan 11 07:14 PM
SIEGALL CLAY BPresident & CEOJan 07Sale144.7317,0442,466,743667,945Jan 11 07:14 PM
DANSEY ROGER DChief Medical OfficerJan 03Sale152.588,6751,323,64879,686Jan 05 05:32 PM
DANSEY ROGER DChief Medical OfficerDec 21Sale155.5828043,56288,361Dec 22 05:33 PM
ROMP CHARLES REVP, CommercialDec 20Sale149.851,323198,25249,973Dec 22 05:34 PM
HIMES VAUGHN BChief Technical OfficerDec 20Sale149.8534551,69859,500Dec 22 05:33 PM
SIEGALL CLAY BPresident & CEODec 20Sale149.851,227183,866667,945Dec 22 05:32 PM
DANSEY ROGER DChief Medical OfficerDec 20Sale149.8528041,95888,641Dec 22 05:33 PM
LIU JEAN IChief Legal OfficerDec 20Sale149.8527641,35970,432Dec 22 05:31 PM
SIMPSON TODD EChief Financial OfficerDec 20Sale149.8534551,698128,458Dec 22 05:31 PM
SIEGALL CLAY BPresident & CEODec 07Option Exercise26.1045,4491,186,219683,863Dec 09 06:49 PM
SIEGALL CLAY BPresident & CEODec 07Sale148.6645,4496,756,632669,172Dec 09 06:49 PM
BAKER BROS. ADVISORS LPDirectorDec 01Sale161.2193,45115,064,9404,069,762Dec 02 06:51 PM
BAKER BROS. ADVISORS LPDirectorNov 30Sale160.33301,44448,331,4514,077,649Dec 02 06:51 PM
HIMES VAUGHN BChief Technical OfficerNov 11Option Exercise26.106,000156,60065,845Nov 12 06:51 PM
HIMES VAUGHN BChief Technical OfficerNov 11Sale178.636,0001,071,77459,845Nov 12 06:51 PM
SIMPSON TODD EChief Financial OfficerNov 04Option Exercise46.372,15699,974128,803Nov 05 05:21 PM
LIU JEAN IGC/EVP, Leg AffairsNov 04Option Exercise46.371,61774,98070,708Nov 05 05:21 PM
SIMPSON TODD EChief Financial OfficerNov 03Option Exercise44.0940,2321,773,829166,879Nov 05 05:21 PM
SIMPSON TODD EChief Financial OfficerNov 03Sale185.0040,2327,442,920126,647Nov 05 05:21 PM
LIU JEAN IGC/EVP, Leg AfairsNov 01Option Exercise35.9534,8761,253,792103,967Nov 03 09:18 PM
HIMES VAUGHN BChief Technical OfficerNov 01Option Exercise46.372,15699,97459,845Nov 03 07:20 PM
LIU JEAN IGC/EVP, Leg AfairsNov 01Sale177.4134,8766,187,36969,091Nov 03 09:18 PM
SIMPSON TODD EChief Financial OfficerOct 29Option Exercise41.0433,5641,377,467160,211Nov 02 06:46 PM
SIMPSON TODD EChief Financial OfficerOct 29Sale180.0033,5646,041,523126,647Nov 02 06:46 PM
HIMES VAUGHN BChief Technical OfficerSep 08Option Exercise26.106,000156,60063,488Sep 10 07:22 PM
HIMES VAUGHN BChief Technical OfficerSep 08Sale150.006,000900,00057,488Sep 10 07:22 PM
DANSEY ROGER DChief Medical OfficerAug 31Sale167.524,611772,41485,339Sep 02 08:07 PM
SIEGALL CLAY BPresident & CEOAug 31Sale167.5214,3512,404,015668,458Sep 02 07:59 PM
LIU JEAN IGC/EVP, Legal AffairsAug 31Sale167.523,648611,09768,931Sep 02 07:58 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale167.523,987667,884126,446Sep 02 07:57 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale167.523,584600,37657,488Sep 02 07:53 PM
ROMP CHARLES REVP, CommercialAug 31Sale167.521,133189,79551,184Sep 02 07:49 PM
SIEGALL CLAY BPresident and CEOAug 31Sale169.9210,4321,772,575682,809Aug 31 09:28 PM
SIEGALL CLAY BPresident and CEOAug 30Sale166.8635,7065,957,816693,241Aug 31 09:28 PM
SIEGALL CLAY BPresident and CEOAug 27Sale169.0514,2942,416,390728,947Aug 31 09:28 PM
ROMP CHARLES REVP, CommercialAug 16Sale154.55777120,08842,410Aug 18 08:29 PM
HIMES VAUGHN BChief Technical OfficerAug 16Sale154.55658101,69752,354Aug 18 08:29 PM
SIEGALL CLAY BPresident & CEOAug 16Sale154.552,789431,051712,420Aug 18 08:29 PM
SIMPSON TODD EChief Financial OfficerAug 16Sale154.5553382,377119,338Aug 18 08:28 PM
LIU JEAN IGC/EVP, Leg AffairsAug 16Sale154.55718110,97063,333Aug 18 08:28 PM
DANSEY ROGER DChief Medical OfficerAug 16Sale154.551,657256,09672,778Aug 18 08:28 PM
DANSEY ROGER DChief Medical OfficerAug 13Sale156.5910,0001,565,86774,435Aug 13 09:39 PM
SIEGALL CLAY BPresident & CEOAug 06Option Exercise15.465,79389,560718,885Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 06Sale159.705,793925,134715,209Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 05Option Exercise15.4623,560364,238724,471Aug 06 08:28 PM
SIEGALL CLAY BPresident & CEOAug 05Sale163.0823,5603,842,086715,209Aug 06 08:28 PM
SIEGALL CLAY BPresident and CEOJul 02Option Exercise15.4615,268236,043722,621Jul 06 09:40 PM
ROMP CHARLES REVP, CommercialJul 02Sale158.41703111,36243,187Jul 06 08:13 PM
SIEGALL CLAY BPresident and CEOJul 02Sale156.3615,2682,387,233715,209Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Option Exercise15.4614,085217,754721,374Jul 06 09:40 PM
SIEGALL CLAY BPresident and CEOJul 01Sale157.7814,0852,222,376715,209Jul 06 09:40 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale152.2225,1093,822,03484,435Jun 21 06:02 PM
HIMES VAUGHN BChief Technical OfficerJun 07Option Exercise26.101,30334,00854,315Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 07Sale150.001,303195,45053,012Jun 08 08:50 PM
HIMES VAUGHN BChief Technical OfficerJun 03Option Exercise15.4610,697165,37663,709Jun 04 08:21 PM
SIEGALL CLAY BPresident and CEOJun 03Option Exercise15.4629,353453,797723,884Jun 04 08:22 PM
SIEGALL CLAY BPresident and CEOJun 03Sale144.5129,3534,241,801715,209Jun 04 08:22 PM
HIMES VAUGHN BChief Technical OfficerJun 03Sale144.9110,6971,550,09053,012Jun 04 08:21 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.